FMP

FMP

Enter

KYMR - Kymera Therapeutics,...

photo-url-https://images.financialmodelingprep.com/symbol/KYMR.png

Kymera Therapeutics, Inc.

KYMR

NASDAQ

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

34.37 USD

0.92 (2.68%)

KYMR Financial Statements

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Total Revenue

7.39M

3.74M

25.65M

10.29M

Cost of Revenue

0

2M

1.9M

1.5M

Gross Profit

7.39M

1.74M

23.75M

8.79M

Operating Expenses

88.15M

75.86M

74.67M

61.69M

Research and Development

71.82M

60.41M

57.3M

48.82M

Selling, General & Administrative Expenses

16.33M

15.46M

17.37M

14.37M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

16.33M

15.46M

17.37M

14.37M

Other Expenses

0

0

0

-47.32M

Operating Income

-80.75M

-72.12M

-50.92M

-52.91M

Total Other Income/Expenses Net

10M

9.64M

8.86M

4.35M

Income Before Tax

-70.75M

-62.49M

-42.06M

-48.56M

Income Tax

0

0

0

39k

Net Income

-70.75M

-62.49M

-42.06M

-48.56M

Basic EPS

-0.88

-0.82

-0.58

-0.69

EPS Diluted

-0.88

-0.82

-0.58

-0.69

Basic Average Shares

79.99M

76.13M

73.06M

70.77M

Diluted Average Shares

79.99M

76.13M

73.06M

70.77M

EBITDA

-68.71M

-60.43M

-40.1M

-46.99M

Retained Earning Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Retained Earnings (Previous Year)

-683.86M

-621.37M

-579.31M

-530.75M

Net Income

-70.75M

-62.49M

-42.06M

-48.56M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-754.61M

-683.86M

-621.37M

-579.31M

Other Distributions

-70.75M

-62.49M

-42.06M

-48.56M

PPE Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Gross PPE

97.86M

99.31M

100.44M

98.67M

Annual Depreciation

1.99M

2M

1.9M

1.5M

Capital Expenditure

-936k

189k

-4.69M

-7.4M

Net PPE

96.81M

97.12M

103.23M

104.57M

Intangible and Goodwill Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep